Opening book details…
About this book
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate by Robert J. Cherney, Prakash Anjanappa, Kumaravel Selvakumar, Douglas G. Batt, Gregory D. Brown, Anne V. Rose, Ragini Vuppugalla, Jing Chen, Jian Pang, Songmei Xu, Melissa Yarde, Andrew J. Tebben, Venkatram Reddy Paidi, Mary Ellen Cvijic, Arvind Mathur,... is a book available to read on EtoBox.
- Author
- Robert J. Cherney, Prakash Anjanappa, Kumaravel Selvakumar, Douglas G. Batt, Gregory D. Brown, Anne V. Rose, Ragini Vuppugalla, Jing Chen, Jian Pang, Songmei Xu, Melissa Yarde, Andrew J. Tebben, Venkatram Reddy Paidi, Mary Ellen Cvijic, Arvind Mathur,...
- Published
- 2021
- Language
- EN
More by Robert J. Cherney, Prakash Anjanappa, Kumaravel Selvakumar, Douglas G. Batt, Gregory D. Brown, Anne V. Rose, Ragini Vuppugalla, Jing Chen, Jian Pang, Songmei Xu, Melissa Yarde, Andrew J. Tebben, Venkatram Reddy Paidi, Mary Ellen Cvijic, Arvind Mathur,...
Similar books
- Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2 — Michael G. Yang, Zili Xiao, Rulin Zhao, Andrew J. Tebben, Bei Wang, Robert J. Cherney, Douglas G. Batt, Gregory D. Brown, Mary Ellen Cvijic, John V. Duncia, Michael A. Gallela, Daniel S. Gardner, Purnima Khandelwal, Mary F. Malley, Jian Pang, Anne V.... (2021)
- Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate — Yan Chen, Hui Li, Rose Yen, Thilo J. Heckrodt, Darren McMurtrie, Rajinder Singh, Vanessa Taylor, Esteban S. Masuda, Gary Park & Donald G. Payan (2022)
- Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1 — Emily C. Cherney, Liping Zhang, Susheel Nara, Xiao Zhu, Johnni Gullo-Brown, Derrick Maley, Tai-An Lin, John T. Hunt, Christine Huang, Zheng Yang, Celia Darienzo, Lorell Discenza, Asoka Ranasinghe, Mary Grubb, Theresa Ziemba, Sarah C. Traeger, Xin Li,... (2021)
- Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis — Joseph Carpenter, Gang Wu, Ying Wang, Erica M. Cook, Tao Wang, Doree Sitkoff, Karen A. Rossi, Kathy Mosure, Xiaoliang Zhuo, Gary G. Cao, Milinda Ziegler, Anthony V. Azzara, Jack Krupinski, Matthew G. Soars, Bruce Alan Ellsworth & Dean A. Wacker (2021)
- Discovery of Dipeptides as Potent Botulinum Neurotoxin A Light-Chain Inhibitors — Martin Amezcua, Ricardo S. Cruz, Alex Ku, Wilfred Moran, Marcos E. Ortega & Nicholas T. Salzameda (2021)
- Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors — Johan J. N. Veerman, Yorik B. Bruseker, Eddy Damen, Erik H. Heijne, Wendy van Bruggen, Koen F. W. Hekking, Rob Winkel, Christopher D. Hupp, Anthony D. Keefe, Julie Liu, Heather A. Thomson, Ying Zhang, John W. Cuozzo, Andrew J. McRiner, Mark J.... (2021)